SYSTEMATIC REVIEW

Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis [version 1; peer review: 1 approved, 1 approved with reservations]

Mohammad Saifur Rohman ¹, Yeni Purnamasari ², Muhammad Ilmawan ², Bagus Aulia Mahdi ³, Fredo Tamara ⁴, Aditya Indra Mahendra ⁴, Mazen Mazen⁴, Teuku Heriansyah ⁵, Muhammad Yamin⁶, Budi Susetio Pikir ⁷, Jonny Karunia Fajar ⁴

¹Brawijaya Cardiovascular Research Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

²Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

³Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60115, Indonesia

⁴Brawijaya Internal Medicine Research Center, Department of Internal Medicine, Faculty of Medicine, Universitas Brawijaya, Malang, East Java, 65145, Indonesia

⁵Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Aceh, 23111, Indonesia

⁶Division of Cardiovascular Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Jakarta, 16424, Indonesia

⁷Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, East Java, 60115, Indonesia

V1 First published: 10 Feb 2020, 9:99
<https://doi.org/10.12688/f1000research.21925.1>
 Latest published: 07 Sep 2020, 9:99
<https://doi.org/10.12688/f1000research.21925.2>

Abstract

Background: There is controversy among physicians regarding the use of dual antiplatelet therapy (DAPT) in acute coronary syndrome (ACS) patients treated with coronary artery bypass grafting (CABG). Moreover, the evidence of previous studies about this topic remained inconclusive. This study aimed to perform a meta-analysis concerning the relation between the risk of major bleeding and the use of different DAPT (clopidogrel or ticagrelor) in ACS patients treated with CABG.

Methods: A meta-analysis was conducted during March to October 2019. Searches were carried out in Pubmed, Embase, Cochrane, and Web of Science. The predictor covariate in our present study was DAPT (clopidogrel or ticagrelor), and the outcome measure was the risk of major bleeding. Sub-group analysis was also performed, where

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 07 Sep 2020			view
version 1 10 Feb 2020	view	view	
1. Jinesh Bahubali Nagavi , Sarada Vilas College of Pharmacy, Mysore, India			
2. Sheng-Hu He , Yangzhou University, Northern			

data were classified into pre- and post-CABG. Furthermore, to determine the correlation and effect estimation, data were analyzed using fixed or random effect model.

Results: A total of 13 studies consisting 34,015 patients treated with clopidogrel and 32,661 patients treated with ticagrelor was included in our study. Our pooled calculation revealed that the incidence of major bleeding was not different significantly between clopidogrel and ticagrelor. In pre- and post-CABG sub-groups, our results also found no significant difference in major bleeding incidence between clopidogrel and ticagrelor groups.

Conclusions: Our meta-analysis clarifies that clopidogrel, compared to ticagrelor, or vice versa, is not associated with the risk of major bleeding in ACS patients treated with CABG.

Keywords

major bleeding, coronary artery bypass grafting, clopidogrel, ticagrelor

Jiangsu People's Hospital, Yangzhou, China

Bing Xu, Yangzhou University, Northern

Jiangsu People's Hospital, Yangzhou, China

3. **Mircea Ovanetz Balasanian**, Institute of Cardiovascular Diseases "Prof. dr. George I.M. Georgescu", Iasi, Romania

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding authors: Fredo Tamara (fredotamara@gmail.com), Teuku Heriansyah (teuku_hery@unsyiah.ac.id), Budi Susetio Pikir (bsp49@fk.unair.ac.id), Jonny Karunia Fajar (gembayok@gmail.com)

Author roles: **Rohman MS:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing; **Purnamasari Y:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Validation, Visualization, Writing – Original Draft Preparation; **Ilmawan M:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Supervision, Validation; **Mahdi BA:** Data Curation, Formal Analysis, Investigation, Methodology, Validation; **Tamara F:** Investigation, Validation; **Mahendra AI:** Formal Analysis, Investigation, Validation; **Mazen M:** Investigation; **Heriansyah T:** Investigation, Supervision, Validation; **Yamin M:** Investigation, Validation; **Pikir BS:** Supervision, Validation, Writing – Review & Editing; **Fajar JK:** Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Supervision, Validation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This project was funded by MIT-Indonesia Research Alliance (MIRA) (No. 23/G/R/V/2019).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Rohman MS *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Rohman MS, Purnamasari Y, Ilmawan M *et al.* **Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2020, 9:99 <https://doi.org/10.12688/f1000research.21925.1>

First published: 10 Feb 2020, 9:99 <https://doi.org/10.12688/f1000research.21925.1>

Introduction

In the last two decades, the management of acute coronary syndrome (ACS) has been well defined and periodically updated. Management has developed drastically over this period¹. Management options are numerous, and they depend on the facilities of the hospital. Of these treatment options, coronary artery bypass grafting (CABG) is considered the most challenging and the final option when other treatment options, including percutaneous coronary intervention (PCI) and thrombolytic therapy, fail to restore blood flow in the infarct-related artery². Moreover, the drugs used in ACS patients in all management options are complex, and dual antiplatelet therapy (DAPT) is commonly used. DAPT is globally used to treat patients with ACS. It was first reported in 1996³, and was first recommended for treating ACS patients in 2007 in American College of Cardiology (ACC)/American Heart Association (AHA) guidelines⁴. Since then, DAPT has been widely used in the early management of ACS patients^{5,6}.

Recently, when performing DAPT, whether to use clopidogrel or ticagrelor (the choice between acetylsalicylic acid (ASA) + clopidogrel and ASA + ticagrelor) has remained controversial due to the current assumption that one of the two might provide higher risk of major bleeding^{7,8}. In the Indonesian National Health Insurance drug catalog, in 2018 clopidogrel was withdrawn and substituted with ticagrelor. However, in the drug price list (<https://e-katalog.lkpp.go.id/>; website in Indonesian), ticagrelor is more expensive than clopidogrel. It is unclear whether the assumptions made about the risk of major bleeding caused by clopidogrel or ticagrelor were supported by the evidence or were possibly the result of conspiracy among pharmaceutical industries to increase their products marketing. Ticagrelor may provide a more potent platelet inhibition effect, therefore reducing the risk of a thrombotic event⁹. In the context of ACS, the greater effect may be accompanied more complications. Therefore, the benefits of DAPT and the risk of complications (bleeding) should balance. In the case of ACS patients undergoing CABG, to prevent major bleeding, it is recommended that DAPT should be discontinued for at least three and five days before elective CABG for ticagrelor and clopidogrel, respectively¹⁰. Furthermore, in the case of emergency or urgent CABG, DAPT should be discontinued prematurely¹¹. The discontinuation of DAPT might increase the risk of a thrombotic event¹². However, delay in CABG had also been shown to associate with poor clinical outcome and increased risk of mortality¹³. Therefore, identifying the appropriate DAPT, whether ticagrelor or clopidogrel, is crucial to prevent the risk of major bleeding. Although 2016 ACC/AHA guidelines recommended ticagrelor over clopidogrel because ticagrelor is considered to have a more potent anti-platelet effect than clopidogrel¹⁴, the evidence from previous studies regarding the association between the risk of major bleeding and the use of different DAPT using either clopidogrel or ticagrelor in ACS patients treated with CABG were inconclusive. Therefore, those inconclusive data of previous studies required clarification using a meta-analysis approach.

Therefore, the present study aimed to perform a meta-analysis whether the use of different DAPT (clopidogrel or

ticagrelor) might affect the risk of major bleeding or not in ACS patients treated with CABG. Our study outcome could clarify the real effect of the use of DAPT (clopidogrel or ticagrelor) to the risk of major bleeding in ACS patients treated with CABG. Moreover, we also expect that our current meta-analysis might correct previous assumptions concerning the use of different DAPT.

Methods

Study design

A Meta-analysis was performed during March to October 2019 to assess the association between the incidence of major bleeding and the use of DAPT either clopidogrel or ticagrelor in ACS patients treated with CABG. In effort to attain our goal, potentially relevant papers were identified and collected from PubMed, Embase, Cochrane, and Web of Science to calculate odd ratio (OR) and 95% confidence interval (95%CI) using either fixed or random effect model. A checklist adapted from Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) and the design of our previous meta-analyses^{15–20} were used to guide the meta-analysis protocols in our present study²¹. See *Reporting guidelines* for a completed PRISMA checklist for this study²².

Search strategy

We conducted a systematic search in PubMed, Embase, Cochrane, and Web of Science up to 20 September 2019. The search strategy, conformed to medical subjects heading (MeSH), involved the use of combination the following keywords: ["Major Bleeding"] AND ["Coronary Artery Bypass Grafting" OR "CABG"] AND ["Dual Anti Platelet Therapy" OR "DAPT"], and ["Clopidogrel" OR "Ticagrelor"]. In our searching strategy, language restrictions were not applied. We only used the study with the larger sample size and that was more up-to-date if we found the same data among studies. Moreover, we also searched the potential papers from the reference list of relevant or eligible studies. We also employed the "related article" option in PubMed to broaden our searching strategy. The potentially relevant papers were identified by two independent investigators (Y.P., M.I.). Disagreement between two independent investigators was resolved by discussion and/or by consulting to the senior investigator (J.K.F.).

Eligibility criteria and data extraction

The inclusion criteria for this study were (1) retrospective studies, (2) prospective studies, (3) randomized controlled trials (RCTs), (4) evaluating the association between the incidence of major bleeding and DAPT either using clopidogrel or ticagrelor in ACS patients treated with CABG, (5) providing sufficient data for calculation of OR with 95% CI. While, articles were excluded if the following criteria were found: (1) irrelevant topic, (2) review, (3) conference presentation, and (4) having low quality (see *Quality assessment*). For data extraction, information related to (1) name of the first author, (2) year of publication, (3) country of origin, (4) sample sizes of case and controls, and (5) the incidence of major bleeding were extracted from each study. To prevent human errors, data extraction was performed by two independent authors. If discrepancy occurred, a consensus or discussion was established.

Covariates and sub-group analysis

The predictor covariate in this study was DAPT either using clopidogrel or ticagrelor. While, the main outcome measure was the incidence of major bleeding in patients receiving both clopidogrel and ticagrelor. The major bleeding included in our analysis was restricted to thrombolysis in myocardial infarction²³ and platelet inhibition and outcomes criteria²⁴. Moreover, to confer a comprehensive analysis, we also performed sub-group analysis. Data were classified into the incidence of major bleeding in ACS patients treated with DAPT (clopidogrel or ticagrelor) before and after CABG.

Quality assessment

To ensure the quality of each study and to avoid the potential bias in each study, the quality of retrieved studies was controlled and collected by two independent investigators (Y.P., M.I.). The quality and risk of bias of each study was assessed using Methodological Index for Non-Randomized Studies (MINORS) score²⁵. The MINORS score ranged from 0 to 24, and consisted of 12 items. Each item was assessed as 0 if the item was not reported, 1 if the item was inadequate reported, and 2 if the item was adequate reported. Each study was interpreted as having low quality if the score was less than or equal to 12, moderate if the score was less than or equal to 16 and more than 12, and high quality if the score was more than 16²⁵. If disagreement was found between two independent authors, consensus was achieved through discussion between the two investigators. If the disagreement was not resolved, a consultation to senior researcher (JKF) was conducted.

Statistical analysis

The comparison and effect estimation of major bleeding between DAPT with clopidogrel and ticagrelor were determined using the Z-test. The pooled calculation and effect estimation were described using forest plots. The model of forest plot for describing the comparison and effect estimation was conformed with a Q test. Before analysis using the Z-test, we evaluated heterogeneity and potential publication bias. A Q-test was employed to evaluate heterogeneity. P-value of less than 0.10 was considered to indicate heterogeneity. If we found heterogeneity, a random effect model was used. While, if heterogeneity was not found, a fixed effect model was used. For testing publication bias, an Egger test was used. A P-value of less than 0.05 was considered significantly having publication bias. All analyses in our study were carried out using Review Manager version 5.3 (RevMan Cochrane, London, UK) and Comprehensive Meta-Analysis (CMA, New Jersey, US) version 2.1.

Results

Eligible studies

A flowchart of article searches and study selection is shown in [Figure 1](#). Initially, 37 articles were identified from the literature search. However, eight of them were excluded because they did not have relevance to the topic, leaving a total of 29 articles. The full text of these articles was retrieved and reviewed; it was found that 16 studies did not meet the eligibility criteria because they were reviews (n=5), commentaries (n=4), family-based studies (n=3), included the same study data (n=2), and not providing sufficient data for calculation

Figure 1. A Flowchart diagram of the article search and study selection.

of OR and 95%CI (n=2). Finally, a total of 13 studies were eligible for our meta-analysis. Baseline characteristics of studies included in our analysis are provided in [Table 1](#).

Data synthesis

A total of 13 studies^{2,26–37}, consisting 34,014 patients treated with clopidogrel and 32,661 patients treated with ticagrelor, were included in our study. Of those, the correlation between the use of DAPT (either clopidogrel or ticagrelor) and the risk of major bleeding was found in only three studies^{29,30,37}. A further ten studies failed to clarify the association^{2,26–28,31–36}. Our calculation revealed ([Figure 2A](#)) that the incidence of major bleeding was not significantly different between clopidogrel and ticagrelor (OR = 1.10, 95%CI = 0.98–1.24, p = 0.0990). Moreover, in pre-CABG sub-group, we included nine studies^{28–33,35–37} consisting of 15,109 patients treated with clopidogrel and 13,939 patients treated with ticagrelor. Our results found ([Figure 2B](#)) that no significant difference of major bleeding incidence was observed between clopidogrel and ticagrelor (OR = 1.19, 95%CI = 0.97–1.45, p = 0.0910). While, in the post-CABG sub-group, a total of four papers^{2,26,27,34} consisting of 18,905 patients treated with clopidogrel and 18,722 patients treated with ticagrelor was enrolled for our analysis. Our pooled data ([Figure 2C](#)) confirmed no significant difference in major bleeding incidence between clopidogrel and ticagrelor (OR = 1.00, 95%CI = 0.93–1.08, p = 0.9230). The summary of correlation and effect estimation between the risk of major bleeding and the use of different DAPT is provided in [Table 2](#).

Heterogeneity and publication bias

Evidence of heterogeneity was assessed using the Q-test. Our analysis found that evidence of heterogeneity (p < 0.10) was observed in overall analysis and pre-CABG sub-group. Therefore, random effect model was applied to determine the correlation and effect estimation. While, for post-CABG sub-group, we used fixed effect model to assess the correlation and effect estimation because we did not find the evidence of heterogeneity. Furthermore, potential publication bias was assessed using an Egger test. Our analysis confirmed that potential publication bias was found in post-CABG sub-group (p < 0.05). In overall analysis and pre-CABG sub-group, we found no publication bias. The summary of study heterogeneity and potential publication is described in [Table 2](#).

Discussion

In our present meta-analysis, we included 13 papers consisting of 34,014 and 32,661 patients treated with clopidogrel and ticagrelor following CABG, respectively. Our current findings confirmed that neither clopidogrel nor ticagrelor was associated with risk of major bleeding among ACS patients treated with CABG. To our knowledge, no previous meta-analysis has reported the comparison between clopidogrel and ticagrelor in the context of CABG. Therefore, we were unable to perform a direct comparison. However, in other case settings, meta-analyses have been conducted in the case of PCI and thrombolytic for treating ACS patients. In the case of PCI for treating ACS patients, the reports from previous meta-analyses

Table 1. Baseline characteristics of studies included in the meta-analysis.

Author and year	Clopidogrel		Ticagrelor		Setting (before/after CABG)	Case	Study design	Country	MINORS
	MB	n	MB	n					
Becker <i>et al.</i> 2011 ²⁶	476	9186	446	9235	after CABG	STEMI & NSTEMI	RCT	Mixed	24
Chang <i>et al.</i> 2019 ²	7	100	7	100	after CABG	NSTEMI	Case - control	Korea	16
Dery <i>et al.</i> 2014 ²⁷	37	328	6	55	after CABG	ACS	Case - control	Canada	18
Dinicolantonio <i>et al.</i> 2013 ²⁸	654	9186	619	9235	before CABG	ACS	Case - control	Mixed	18
Gajayana <i>et al.</i> 2018 ²⁹	44	1721	7	860	before CABG	ACS	Case - control	USA	17
Hansson <i>et al.</i> 2014 ³⁰	213	232	166	173	before CABG	ACS	Case - control	Sweden	24
Hansson <i>et al.</i> 2016 ³¹	95	978	90	1266	before CABG	ACS	Case - control	Sweden	19
Held <i>et al.</i> 2011 ³²	375	629	362	632	before CABG	ACS	Case - control	US	24
Holm <i>et al.</i> 2019 ³³	474	1293	381	1018	before CABG	ACS	Cohort	Mixed	24
Kang <i>et al.</i> 2015 ³⁴	929	9291	961	9332	after CABG	ACS	Case - control	Hong Kong	23
Russo <i>et al.</i> 2018 ³⁵	19	413	5	95	before CABG	ACS	Case - control	Canada	22
Schaefer <i>et al.</i> 2016 ³⁶	0	28	2	28	before CABG	ACS	Case - control	Germany	14
Varenhorst <i>et al.</i> 2012 ³⁷	62	629	32	632	before CABG	ACS	RCT	Mixed	24

MB, major bleeding; n, sample size; CABG, coronary artery bypass grafting; RCT, randomized controlled trial; MINORS, Methodological Index for Non-Randomized Studies; STEMI, ST-Elevation Myocardial Infarction; NSTEMI, Non-ST-elevation myocardial infarction; ACS, acute coronary syndrome.

A).

B).

C).

Figure 2. Forest plot of major bleeding comparison between clopidogrel and ticagrelor. (A) Overall analysis. (B) Pre-coronary artery bypass grafting (CABG) sub-group. (C) Post-CABG sub-group.

Table 2. Summary of the association between the use of different dual antiplatelet therapies and the risk of major bleeding.

Parameters	Clopidogrel		Ticagrelor		Model	OR	95%CI	pHet	pE	P-value
	MB, n [%]	Patients, n	MB, n [%]	Patients, n						
Overall analysis	3,385 [9.95]	34,014	3084 [9.44]	32,661	Random	1.10	0.98–1.24	0.0050	0.1310	0.0990
Pre-CABG sub-group	1,936 [12.81]	15,109	1664 [11.94]	13,939	Random	1.19	0.97–1.45	0.0020	0.2060	0.0910
Post-CABG sub-group	1,449 [7.66]	18,905	1,420 [7.58]	18,722	Fixed	1.00	0.93–1.08	0.6470	<0.0001	0.9230

CABG, coronary artery bypass grafting; MB, major bleeding; OR, odds ratio; CI, confidence interval; pHet, p heterogeneity; pE, p Egger.

remained conflicting. A study conducted by Fan *et al.*³⁸ found that clopidogrel was associated with increased risk of major bleeding compared to ticagrelor. On the other hand, Guan *et al.*³⁹ revealed that ticagrelor was proven to correlate with increased risk of major bleeding compared to clopidogrel. A meta-analysis conducted by Westman *et al.*⁴⁰ involved 15 papers, consisting of 26,093 patients treated with clopidogrel and 7,192 patients treated with ticagrelor. The authors revealed that although ticagrelor was associated with increased risk of minor bleeding compared to clopidogrel, the incidence of major bleeding was not significantly different between ticagrelor and clopidogrel. Moreover, in the case of fibrinolytic, a meta-analysis involving three RCTs showed that neither ticagrelor nor clopidogrel was correlated with the risk of major bleeding⁴¹. Furthermore, in the case of ACS, a meta-analysis involving 10 studies revealed that the risk of bleeding was not significantly different between patients receiving clopidogrel and ticagrelor⁴². Therefore, it makes sense that in our current meta-analysis, no association was observed between the use of DAPT either clopidogrel or ticagrelor and the risk of major bleeding.

To provide a comprehensive analysis, we also performed subgroup analysis, divided into pre- and post-CABG. Our findings in sub-group analysis were consistent with our main findings, we emphasized that the incidence of major bleeding either in pre- and post-CABG was not significantly different between clopidogrel and ticagrelor. To our knowledge, until now the major bleeding effect of clopidogrel and ticagrelor in the setting of before and after CABG has not been well defined. Besides the existence of no previous meta-analysis concerning this subject, reports in other case settings did not assess this effect in the pre- or post-intervention context of. Hence, the possible direct and indirect explanations was difficult to clarify. To date, the major bleeding effect of DAPT therapy before and after CABG remained conflicting. A previous study revealed that discontinuation of DAPT therapy 24–72 hours before emergency CABG was proven to increase the risk of major bleeding³⁵. Moreover, Deo *et al.*⁴³ also reported that increased risk of major bleeding was observed in post CABG patients treated with ASA and clopidogrel. However, a study by Solo *et al.*⁴⁴ might support our findings. They evaluated the incidence of major bleeding between ASA and clopidogrel and ASA and ticagrelor. Although statistical analysis was not directly performed, they confirmed that the risk of major bleeding in post CABG patients among different anti-platelets had no strong evidence. Therefore, due to inconclusive reports regarding

the risk of major bleeding and DAPT therapy before and after CABG, further studies are required to clarify our current findings.

The theory underlying the risk of major bleeding due to clopidogrel or ticagrelor is not well defined. However, some theories have been proposed. To stimulate inhibition of platelet aggregation, both clopidogrel and ticagrelor are P2Y₁₂ antagonists. However, associated with the risk of major bleeding, each agent has a different mechanism. Clopidogrel is known to irreversibly induce bleeding by inhibiting P2Y₁₂ receptors, and may cause persistent blockade of the adenosine diphosphate (ADP) binding site. Those inhibitory effects may persist until the platelets are renewed in 7–10 days⁴⁵. Therefore, as it has a longer inhibitory effect than ticagrelor, those treated with clopidogrel may be more vulnerable to risk of bleeding than ticagrelor⁴². Ticagrelor is a reversible P2Y₁₂ receptor antagonist. It works directly on P2Y₁₂ receptors, and therefore may produce rapid inhibition effects and provide rapid recovery of platelet function⁴⁶. It has been already reported that ticagrelor has faster onset and offset than clopidogrel⁴⁷. As a result, when each drug is stopped, the effect of ticagrelor may disappear faster than clopidogrel. In animal subjects, a study proposed that clopidogrel was found to have 3.5-fold associated with higher bleeding risk compared to ticagrelor⁴⁸. Clopidogrel is metabolized by cytochrome P2C19 enzyme⁴⁹, and recent gene-disease interaction studies reported that cytochrome P2C19 CYP2C19*20 C-889T>G (SNP rs11568732) was associated with the risk of bleeding in ACS patients treated with clopidogrel^{50–52}. Therefore, theoretically, the risk of major bleeding with clopidogrel should be higher than with ticagrelor. However, the evidence from previous large-scale studies, including our present meta-analysis, are conflicting and have not clarified the association. Hence, because it was not supported by the evidence, in our opinion, the risk of major bleeding due to different DAPT, for this time being, might be considered as a hypothesis. In the near future, we expected that more complex study designs might be applied to elucidate the real association between the risk of major bleeding and the use of different DAPT.

To the best of our knowledge, our present study was the first meta-analysis assessing the association between the risk of major bleeding and the use of different DAPT in ACS patients treated with CABG. Our current meta-analysis might clarify the inconclusive findings of previous studies regarding this topic,

and we emphasized that clopidogrel, compared to ticagrelor, or vice versa, was not associated with the risk of major bleeding in ACS patients treated with CABG. In the last decade, the use of DAPT, either clopidogrel or ticagrelor, has brought about a dilemma for physicians due to the assumption that one of them was considered to trigger the risk of major bleeding. This dilemma was worsened owing to drug marketing competition among pharmaceutical industries to recommend ticagrelor over clopidogrel. However, our present study indicates that the dilemma was not supported by evidence, and therefore the dilemma might be considered as “the ocean without the waves”. The present meta-analysis emphasizes the safety of DAPT administration, either clopidogrel or ticagrelor, in the context of the risk of major bleeding, and hence we expect that our present meta-analysis might reduce the dilemma regarding the risk of major bleeding due to the use of DAPT either clopidogrel or ticagrelor among physicians. The management of ACS patients using CABG has developed in the last decade, and therefore the use of DAPT in CABG management should conform with the adequate evidence. Furthermore, we hope that our current meta-analysis might be involved in the future revision of CABG management for treating patients with ACS.

In our present study, several crucial limitations were observed. First, some factors that might contribute to the risk of major bleeding, such as coagulation factors, history of stroke, chronic kidney disease, hyperglycemia, and anemia⁵³, were not included and controlled for. Second, our current findings should be interpreted with caution due to relatively small sample size. Third, more than a half of our included studies were cross-sectional studies. Therefore, further studies with higher study design are required to obtain better evidence. Fourth,

human factors (skills) were not involved in the analysis. Fifth, other drugs that might govern the risk of bleeding were not analyzed.

Conclusion

Our meta-analysis reveals that the use of different DAPT either clopidogrel or ticagrelor is not associated with the risk of major bleeding in ACS patients treated with CABG. Our sub-group analysis also fails to confirm this association both in pre- and post-CABG sub-groups. Our findings may provide the clarification of previous conflicting studies in the context of the risk of major bleeding and the use of different DAPT in ACS patients treated with CABG. We also expect that our findings may contribute to the future recommendation of the use of DAPT among ACS patients treated with CABG.

Data availability

Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

Reporting guidelines

Figshare: PRISMA checklist for ‘Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis’. <https://doi.org/10.6084/m9.figshare.11688525.v1>²².

Acknowledgements

We thank MIT-Indonesia Research Alliance (MIRA), Lembaga Pengelola Dana Pendidikan (LPDP), and DSKF publishing campus for supporting our project.

References

- Burlacu A, Tinica G, Nedelciuc I, *et al.*: **Strategies to Lower In-Hospital Mortality in STEMI Patients with Primary PCI: Analysing Two Years Data from a High-Volume Interventional Centre.** *J Interv Cardiol.* 2019; 2019: 3402081.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Chang HW, Kim HJ, Yoo JS, *et al.*: **Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting.** *J Clin Med.* 2019; 8(1): pii: E104.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Schomig A, Neumann FJ, Kastrati A, *et al.*: **A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.** *N Engl J Med.* 1996; 334(17): 1084–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Anderson JL, Adams CD, Antman EM, *et al.*: **ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons; endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.** *Circulation.* 2007; 116(7): e148–304.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Amsterdam EA, Wenger NK, Brindis RG, *et al.*: **2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.** *J Am Coll Cardiol.* 2014; 64(24): e139–e228.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Roffi M, Patrono C, Collet JP, *et al.*: **2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).** *Eur Heart J.* 2016; 37(3): 267–315.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Arora S, Shemisa K, Vaduganathan M, *et al.*: **Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week.** *J Am Coll Cardiol.* 2019; 73(19): 2454–64.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Li B, Jin X, Wang L, *et al.*: **Loss of dominance of ticagrelor over clopidogrel in East Asian patients with acute coronary syndrome.** *Int J Clin Exp Med.* 2019; 12(5): 4528–39.
[Reference Source](#)
- Jiang Z, Zhang R, Sun M, *et al.*: **Effect of Clopidogrel vs Ticagrelor on Platelet Aggregation and Inflammation Markers After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.** *Can J Cardiol.* 2018; 34(12): 1606–12.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Valgimigli M, Bueno H, Byrne RA, *et al.*: **2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with**

EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2018; 39(3): 213–60.
[PubMed Abstract](#) | [Publisher Full Text](#)

11. Wallentin L, Becker RC, Budaj A, *et al.*: **Ticagrelor versus clopidogrel in patients with acute coronary syndromes.** *N Engl J Med.* 2009; 361(11): 1045–57.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Gimbel ME, Minderhoud SCS, Ten Berg JM: **A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment.** *Neth Heart J.* 2018; 26(6): 341–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Sobolev BG, Levy AR, Kuramoto L, *et al.*: **The risk of death associated with delayed coronary artery bypass surgery.** *BMC Health Serv Res.* 2006; 6: 85.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Levine GN, Bates ER, Bittl JA, *et al.*: **2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery.** *Circulation.* 2016; 134(10): e123–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Fajar JK, Andalas M, Harapan H: **Comparison of Apgar scores in breech presentations between vaginal and cesarean delivery.** *Ci Ji Yi Xue Za Zhi.* 2017; 29(1): 24–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
16. Fajar JK, Harapan H: **Socioeconomic and attitudinal variables associated with acceptance and willingness to pay towards dengue vaccine: a systematic review.** *Arch Clin Infect Dis.* 2017; 12(3): e13914.
[Publisher Full Text](#)
17. Fajar JK, Heriansyah T, Rohman MS: **The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: A meta-analysis.** *Indian Heart J.* 2018; 70(Suppl 3): S406–S18.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Fajar JK, Mahendra AI, Tamara F, *et al.*: **The Association Between Complete Blood Count and the Risk of Coronary Heart Disease.** *Turkiye Klinikleri J Med Sci.* 2019; 39(1): 56–64.
[Publisher Full Text](#)
19. Fajar JK, Taufan T, Syarif M, *et al.*: **Hip geometry and femoral neck fractures: A meta-analysis.** *J Orthop Translat.* 2018; 13: 1–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Prihatiningsih S, Fajar JK, Tamara F, *et al.*: **Risk factors of tuberculosis infection among health care workers: a meta-analysis.** *Indian J Tuberc.* 2019.
[Publisher Full Text](#)
21. Moher D, Liberati A, Tetzlaff J, *et al.*: **Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.** *PLoS Med.* 2009; 6(7): e1000097.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Fajar JK: **PRISMA: Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis.** *figshare.* Dataset. 2020.
<http://www.doi.org/10.6084/m9.figshare.11688525.v1>
23. Mehran R, Rao SV, Bhatt DL, *et al.*: **Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.** *Circulation.* 2011; 123(23): 2736–47.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Husted S, James SK, Bach RG, *et al.*: **The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATElet inhibition and patient Outcomes (PLATO) trial.** *Eur Heart J.* 2014; 35(23): 1541–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Slim K, Nini E, Forestier D, *et al.*: **Methodological index for non-randomized studies (minors): development and validation of a new instrument.** *ANZ J Surg.* 2003; 73(9): 712–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Becker RC, Bassand JP, Budaj A, *et al.*: **Bleeding complications with the P2Y₁₂ receptor antagonists clopidogrel and ticagrelor in the PLATElet inhibition and patient Outcomes (PLATO) trial.** *Eur Heart J.* 2011; 32(23): 2933–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Dery J, Dagenais F, Mohammadi S, *et al.*: **Risk of bleeding complications in patients treated with ticagrelor undergoing urgent coronary artery bypass grafting surgery: a single center experience.** *Can J Cardiol.* 2014; 30(10): S328.
[Publisher Full Text](#)
28. DiNicolantonio JJ, D'Ascenzo F, Tomek A, *et al.*: **Clopidogrel is safer than ticagrelor in regard to bleeds: a closer look at the PLATO trial.** *Int J Cardiol.* 2013; 168(3): 1739–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Gajana D, Weintraub WS, Kolm P, *et al.*: **The impact of in-hospital P2Y₁₂ inhibitor switch in patients with acute coronary syndrome.** *Cardiovasc Revasc Med.* 2018; 19(8): 912–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Hansson EC, Jideus L, Aberg B, *et al.*: **Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study.** *Eur Heart J.* 2016; 37(2): 189–97.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Hansson EC, Rexius H, Dellborg M, *et al.*: **Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.** *Eur J Cardiothorac Surg.* 2014; 46(4): 699–705.
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Held C, Asenblad N, Bassand JP, *et al.*: **Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.** *J Am Coll Cardiol.* 2011; 57(6): 672–84.
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Holm M, Biancari F, Khodabandeh S, *et al.*: **Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting.** *Ann Thorac Surg.* 2019; 107(6): 1690–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Kang HJ, Clare RM, Gao R, *et al.*: **Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.** *Am Heart J.* 2015; 169(6): 899–905.e1.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Russo JJ, James TE, Ruel M, *et al.*: **Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y₁₂ receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery.** *Eur Heart J Acute Cardiovasc Care.* 2008; 2048872617740832.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Schaefer A, Sill B, Schoenebeck J, *et al.*: **Preoperative Ticagrelor administration leads to a higher risk of bleeding during and after coronary bypass surgery in a case-matched analysis.** *Interact Cardiovasc Thorac Surg.* 2016; 22(2): 136–40.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Varenhorst C, Alström U, Scirica BM, *et al.*: **Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.** *J Am Coll Cardiol.* 2012; 60(17): 1623–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Fan ZG, Zhang WL, Xu B, *et al.*: **Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis.** *Drug Des Devel Ther.* 2019; 13: 719–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Guan W, Lu H, Yang K: **Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention: A systematic review and Meta-Analysis (2007–2017).** *Medicine (Baltimore).* 2018; 97(43): e12978.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Westman PC, Lipinski MJ, Torguson R, *et al.*: **A comparison of cangrelor, prasugrel, ticagrelor, and clopidogrel in patients undergoing percutaneous coronary intervention: A network meta-analysis.** *Cardiovasc Revasc Med.* 2017; 18(2): 79–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Kheiri B, Osman M, Abdalla A, *et al.*: **Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.** *J Thromb Thrombolysis.* 2018; 46(3): 299–303.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Wang D, Yang XH, Zhang JD, *et al.*: **Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis.** *BMC Cardiovasc Disord.* 2018; 18(1): 217.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Deo SV, Dunlay SM, Shah IK, *et al.*: **Dual anti-platelet therapy after coronary artery bypass grafting: is there any benefit? A systematic review and meta-analysis.** *J Card Surg.* 2013; 28(2): 109–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
44. Solo K, Lavi S, Kabali C, *et al.*: **Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis.** *BMJ.* 2019; 367: 15476.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Becker RC, Gurbel PA: **Platelet P2Y₁₂ receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies.** *Thromb Haemost.* 2010; 103(3): 535–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. VAN Giezen JJ, Nilsson L, Berntsson P, *et al.*: **Ticagrelor binds to human P2Y₁₂ independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation.** *J Thromb Haemost.* 2009; 7(9): 1556–65.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Gurbel PA, Bliden KP, Butler K, *et al.*: **Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.** *Circulation.* 2009; 120(25): 2577–85.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. van Giezen JJ, Berntsson P, Zachrisson H, *et al.*: **Comparison of ticagrelor**

- and thienopyridine P2Y₁₂ binding characteristics and antithrombotic and bleeding effects in rat and dog models of thrombosis/hemostasis. *Thromb Res.* 2009; **124**(5): 565–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Sangkuhl K, Klein TE, Altman RB: Clopidogrel pathway. *Pharmacogenet Genomics.* 2010; **20**(7): 463–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 50. Wallentin L, James S, Storey RF, *et al.*: Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. *Lancet.* 2010; **376**(9749): 1320–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
 51. Novkovic M, Matic D, Kusic-Tisma J, *et al.*: Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. *Eur J Clin Pharmacol.* 2018; **74**(4): 443–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Mirabbasi SA, Khalighi K, Wu Y, *et al.*: CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. *J Community Hosp Intern Med Perspect.* 2017; **7**(3): 151–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, *et al.*: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost.* 2005; **3**(4): 692–4.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 25 August 2020

<https://doi.org/10.5256/f1000research.24175.r69370>

© 2020 He S et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sheng-Hu He

Department of Cardiology, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China

Bing Xu

Department of Cardiology, Clinical Medical College, Yangzhou University, Northern Jiangsu People's Hospital, Yangzhou, China

This systematic review and meta-analysis aimed to compare the risk of major bleeding between clopidogrel and ticagrelor in ACS patients treated with CABG. It is a meaningful clinical topic that needs more support from evidence-based medicine. According to the results of this study, ticagrelor should be used more confidently in ACS patients treated with CABG.

However, there are disadvantages in some issues:

1. The characteristic summary of the 13 included trials was not shown in the manuscript. It is an important part of a meta-analysis, which should contain the data of age, gender, race, doses of medication, and bleeding risk scores.
2. Because only 2 of them are RCTs, most of them are case-control trails, the methodological bias of the included studies should be analyzed. There are many methods that can estimate the qualities of the included studies, at least one of them should be used in this study to remind the readers interpreting the results with caution.
3. Although this study has analyzed the main observation, the risk of major bleeding, and did subgroup analysis for pre-surgery and post-surgery patients, other factors should be considered using subgroup analysis, for example, race, region, dose and time, bleeding risk scores if possible.
4. The logic of the discussion is not very clear. The structure of this part should be modified, some points should be simplified, and some duplicate expressions should be removed to make readers understand quicker and easier.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Interventional cardiology

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 01 Sep 2020

Jonny Fajar, Universitas Brawijaya, Malang, Indonesia

1. This systematic review and meta-analysis aimed to compare the risk of major bleeding between clopidogrel and ticagrelor in ACS patients treated with CABG. It is a meaningful clinical topic that needs more support from evidence-based medicine. According to the results of this study, ticagrelor should be used more confidently in ACS patients treated with CABG. However, there are disadvantages in some issues: The characteristic summary of the 13 included trials was not shown in the manuscript. It is an important part of a meta-analysis, which should contain the data of age, gender, race, doses of medication, and bleeding risk scores.

Response: We have provided the additional characteristics in Table 1.

2. Because only 2 of them are RCTs, most of them are case-control trails, the methodological bias of the included studies should be analyzed. There are many methods that can estimate the qualities of the included studies, at least one of them should be used in this study to remind the readers interpreting the results with caution.

Response: The additional information regarding the possibility of methodological bias and to interpret our results with caution has been provided in study limitations.
"Third, more than a half of our included studies were cross-sectional studies, and might provide the methodological bias. Therefore, our results should be interpreted with caution."

3. Although this study has analyzed the main observation, the risk of major bleeding, and did subgroup analysis for pre-surgery and post-surgery patients, other factors should be considered using subgroup analysis, for example, race, region, dose and time, bleeding risk scores if possible.

Response: We have tried to perform sub-group analyses in accordance with ethnicity, region, dose, and bleeding risk score; however, the data were imbalanced, and therefore the calculation was unable to be performed.

4. The logic of the discussion is not very clear. The structure of this part should be modified, some points should be simplified, and some duplicate expressions should be removed to make readers understand quicker and easier.

Response: We have revised our manuscript in some part to increase the consistency of the text and to avoid the unnecessary repetition without changing the meanings or findings.

Competing Interests: We have no competing interest.

Reviewer Report 23 June 2020

<https://doi.org/10.5256/f1000research.24175.r61678>

© 2020 Nagavi J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jinesh Bahubali Nagavi

Sarada Vilas College of Pharmacy, Mysore, Karnataka, India

- The article is well explained with all the data and results.
- The conclusion is very short and precise.
- Search strategy should be elaborated.
- Objectives should be mentioned clearly in the abstract.
- The discussion part is explained well in detail.
- Statistical analysis and its interpretation is appropriate
- Choice of references is very opt and good.

Are the rationale for, and objectives of, the Systematic Review clearly stated?

Yes

Are sufficient details of the methods and analysis provided to allow replication by others?

Yes

Is the statistical analysis and its interpretation appropriate?

Yes

Are the conclusions drawn adequately supported by the results presented in the review?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Drug interaction studies

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 01 Sep 2020

Jonny Fajar, Universitas Brawijaya, Malang, Indonesia

Thank you for reviewer comments. We have revised our manuscript in some part to increase the consistency of the text without changing the meanings or findings.

1. The article is well explained with all the data and results.

Response: Thank you.

2. The conclusion is very short and precise.

Response: Thank you.

3. Search strategy should be elaborated.

Response: The search strategy has been provided in methods.

"Search strategy

We conducted a systematic search in PubMed, Embase, Cochrane, and Web of Science up to 20 September 2019. The search strategy, conformed to medical subjects heading (MeSH), involved the use of combination the following keywords: ["Major Bleeding"] AND ["Coronary Artery Bypass Grafting" OR "CABG"] AND ["Dual Anti Platelet Therapy" OR "DAPT"], and ["Clopidogrel" OR "Ticagrelor"]. In our searching strategy, language restrictions were not applied. We only used the study with the larger sample size and that was more up-to-date if we found the same data among studies. Moreover, we also searched the potential papers from the reference list of relevant or eligible studies. We also employed the "related article" option in PubMed to broaden our searching strategy. The potentially relevant papers were identified by two independent investigators (Y.P., M.I.). Disagreement between two independent investigators was resolved by discussion and/or by consulting to the senior investigator (J.K.F.)."

4. Objectives should be mentioned clearly in the abstract.

Response: The objective of our study has been outlined in abstract.

"This study aimed to perform a meta-analysis concerning the relation between the risk of major bleeding and the use of different DAPT (clopidogrel or ticagrelor) in ACS patients treated with CABG."

5. The discussion part is explained well in detail.

Response: Thank you.

6. Statistical analysis and its interpretation is appropriate.

Response: Thank you.

7. Choice of references is very opt and good.

Response: Thank you.

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research